Literature DB >> 31676153

Urocortin 2 Gene Transfer Improves Heart Function in Aged Mice.

Dimosthenis Giamouridis1, Mei Hua Gao2, N Chin Lai2, Tracy Guo2, Atsushi Miyanohara3, W Matthijs Blankesteijn4, Erik A L Biessen5, H Kirk Hammond6.   

Abstract

Prevalence of left ventricular (LV) systolic and diastolic dysfunction increases with aging. We previously reported that urocortin 2 (Ucn2) gene transfer increases heart function in mice with heart failure with reduced ejection fraction. Here, we test the hypotheses that (1) Ucn2 gene transfer will increase LV function in aged mice and that (2) Ucn2 gene transfer given in early life will prevent age-related LV dysfunction. Nineteen-month-old (treatment study) and 3-month-old (prevention study) mice received Ucn2 gene transfer or saline. LV function was examined 3-4 months (treatment study) or 20 months (prevention study) after Ucn2 gene transfer or saline injection. In both the treatment and prevention strategies, Ucn2 gene transfer increased ejection fraction, reduced LV volume, increased LV peak -dP/dt and peak +dP/dt, and reduced global longitudinal strain. Ucn2 gene transfer-in both treatment and prevention strategies-was associated with higher levels of LV SERCA2a protein, reduced phosphorylation of LV CaMKIIa, and reduced LV α-skeletal actin mRNA expression (reflecting reduced cardiac stress). In conclusion, Ucn2 gene transfer restores normal cardiac function in mice with age-related LV dysfunction and prevents development of LV dysfunction. Published by Elsevier Inc.

Entities:  

Keywords:  AAV; HFpEF; LV strain; age-related LV dysfunction; contractile function; diastolic function; gene transfer; urocortin 2

Year:  2019        PMID: 31676153      PMCID: PMC6953892          DOI: 10.1016/j.ymthe.2019.10.003

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

1.  Force-frequency effect is a powerful determinant of myocardial contractility in the mouse.

Authors:  V Palakodeti; S Oh; B H Oh; L Mao; M Hongo; K L Peterson; J Ross
Journal:  Am J Physiol       Date:  1997-09

2.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 3.  Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction.

Authors:  Kashif Kalam; Petr Otahal; Thomas H Marwick
Journal:  Heart       Date:  2014-05-23       Impact factor: 5.994

4.  Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.

Authors:  Darnel Prakoso; Miles J De Blasio; Chengxue Qin; Sarah Rosli; Helen Kiriazis; Hongwei Qian; Xiao-Jun Du; Kate L Weeks; Paul Gregorevic; Julie R McMullen; Rebecca H Ritchie
Journal:  Clin Sci (Lond)       Date:  2017-06-07       Impact factor: 6.124

Review 5.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

6.  Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.

Authors:  Mihai Gheorghiade; Stephen J Greene; Piotr Ponikowski; Aldo P Maggioni; Jerzy Korewicki; Cezar Macarie; Marco Metra; Jacek Grzybowski; Serban-Ion Bubenek-Turconi; Waldemar Radziszewski; Allan Olson; Orlando F Bueno; Atalanta Ghosh; Lawrence I Deckelbaum; Lilian Y Li; Ayan R Patel; Andreas Koester; Marvin A Konstam
Journal:  Eur J Heart Fail       Date:  2013-03-06       Impact factor: 15.534

7.  Exacerbated cardiac fibrosis induced by β-adrenergic activation in old mice due to decreased AMPK activity.

Authors:  Jingjing Wang; Yao Song; Hao Li; Qiang Shen; Jing Shen; Xiangbo An; Jimin Wu; Jianshu Zhang; Yunong Wu; Han Xiao; Youyi Zhang
Journal:  Clin Exp Pharmacol Physiol       Date:  2016-11       Impact factor: 2.557

8.  Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure.

Authors:  Colin G Stirrat; Sowmya Venkatasubramanian; Tania Pawade; Andrew J Mitchell; Anoop S Shah; Ninian N Lang; David E Newby
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

9.  Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal.

Authors:  Dimosthenis Giamouridis; Mei Hua Gao; N Chin Lai; Zhen Tan; Young Chul Kim; Tracy Guo; Atsushi Miyanohara; W Matthijs Blankesteijn; Erik Biessen; H Kirk Hammond
Journal:  JACC Basic Transl Sci       Date:  2018-05-30

10.  Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.

Authors:  N Chin Lai; Mei Hua Gao; Dimosthenis Giamouridis; Jorge Suarez; Atsushi Miyanohara; Jay Parikh; Stephen Hightower; Tracy Guo; Wolfgang Dillmann; Young-Chul Kim; Julieta Diaz-Juarez; H Kirk Hammond
Journal:  Hum Gene Ther       Date:  2015-04-09       Impact factor: 5.695

View more
  1 in total

1.  Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation.

Authors:  Isabel Mayoral-González; Eva M Calderón-Sánchez; Isabel Galeano-Otero; Marta Martín-Bórnez; Encarnación Gutiérrez-Carretero; María Fernández-Velasco; Nieves Domenech; María Generosa Crespo-Leiro; Ana María Gómez; Antonio Ordóñez-Fernández; Abdelkrim Hmadcha; Tarik Smani
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-10       Impact factor: 8.886

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.